e-Drug3D 1601 |
cas 10040-45-6 |
CLASS METABOLISM |
ROUTE (list) ORAL |
PK parameters Tmax 7 HOUR |
Target - |
DrugCentral Unknown |
Download SDF file | Phenol, 4,4'-(2-pyridinylmethylene)bis-, 1,1'-bis(hydrogen sulfate), sodium salt (1:2) Formula: Calculated chemical properties: MW 437.45 NB_atoms 29 XLogP 2.63 PSA 140.107 NB_HD 2 NB_HA 9 fsp3 0.06 Lipinski(0=no;1=yes) 0 |
FDA NDA 202535 (label) INN (CITRIC ACID ; MAGNESIUM OXIDE ; SODIUM PICOSULFATE) PREPOPIK (FERRING PHARMS INC) APPROVAL= AP YEAR= 2012 DISCONTINUED NDA 205743 (pdf not found) INN (CITRIC ACID ; MAGNESIUM OXIDE ; SODIUM PICOSULFATE) CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE (PAR PHARM INC) APPROVAL= TA YEAR= 2016 NDA 209589 (label) INN (CITRIC ACID ; MAGNESIUM OXIDE ; SODIUM PICOSULFATE) CLENPIQ (FERRING PHARMS INC) APPROVAL= AP YEAR= 2017 NDA 212789 (pdf not found) INN (CITRIC ACID ; MAGNESIUM OXIDE ; SODIUM PICOSULFATE) SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID (HETERO LABS LTD V) APPROVAL= AP YEAR= 2022 |
Other links: | ||
e-Drug3D 1608 |
cas 603-41-8 |
CLASS METABOLISM |
ROUTE (list) - |
PK parameters |
Target - |
DrugCentral Unknown |
Download SDF file | Phenol, 4,4'-(2-pyridinylmethylene)bis- Formula: Calculated chemical properties: MW 277.31 NB_atoms 21 XLogP 3.67 PSA 52.846 NB_HD 2 NB_HA 3 fsp3 0.06 Lipinski(0=no;1=yes) 1 |
FDA - |
Other links: |